NKGen Biotech Inc. (OTC:NKGN) Financings
Financings
| Raise | Date |
|---|---|
| Funding (terms to be finalized) Closed: US$17M raised Buyers: AlpineBrook Capital GP 1 Limited (provided the majority of the $17 million funding); Dr. Paul Y. Song (provided the remainder of the funding) Insiders: NKGen CEO Dr. Paul Y. Song provided part of the funding alongside AlpineBrook Use of proceeds: Purchase of NKMax Co., Ltd. shares | Sep 9, 2025 |
| Private placement of shares of common stock and warrants Closed: US$2M raised · US$0.25 a share Buyers: Japanese strategic investor ($2 million) Use of proceeds: Resources to regain compliance with reporting obligations and listing standards | Jul 16, 2025 |
| Private placement of shares of common stock and warrants Closed: US$2.65M raised Buyers: Paul Y. Song, M.D. ($2.65 million in shares of common stock and warrants) Insiders: Chairman & CEO Paul Y. Song, M.D. invested $2.65 million cash in shares of common stock and warrants Use of proceeds: Accelerate Phase 2 Alzheimer's trial, reduce payables, general working capital and public company compliance expenses | May 8, 2025 |